You can access any of the podium or poster presentations’ abstracts by searching for it below. For the 2026 FIP world congress in Montreal, presentations and summaries from invited speakers are available below, while abstracts are published in the Pharmacy Education Journal (PEJ) here.
Export this Abstract | Print this Abstract |
Add to my preferred Abstracts list |
My preferred Abstracts list (0) |
Back to Search
AMANTADINE DEVELOPS DRUG TOXIC SYMPTOM IN A PATIENT WITH LATE EFFECTS OF CEREBRAL INFARCTION
- At: AbuDhabi (United Arab Emirates) (2019)
- Type: Poster
- Poster code: POS-HMIS-032
- By: WATANABE, Yoshiteru (Tohoku Medical and Pharmaceutical University Hospital, Pharmacy, Japan)
- Co-author(s): Yoshiteru Watanabe: Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan
Takashi Uno: Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan
Miho Utsumi: Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan
Masashi Nakamura: Neurology, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan
Kensuke Usui: Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan
Kouji Okada: Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan
Eiji Suzuki: Psychiatry, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan
Ichiro Nakashima: Neurology, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan - Abstract:
Background
Amantadine acts on dopamine neurons and is used to treat the symptoms of Parkinson's disease. This drug improves the spontaneity decrease with late effects of cerebral infarction.
Methods
A 70s-year-old female patient with cerebral infraction was hospitalized in our hospital and she was treated for the acute phase.Results
On the
.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 23 September 2026